Snowball logo
logo
MDCL_logo

MedinCell S.A

MDCLF • PINK
$34.39$0.00  (0%)
Estimate
EPS
-1.09
Beta
0.917
About the company
Ticker
MDCLF
ISIN
Country
France
Sector (GICS)
Healthcare
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.

Frequently asked questions

What sector does MedinCell S.A (MDCLF) operate in?

MedinCell S.A belongs to the Healthcare sector and operates in the Biotechnology industry.

What is MedinCell S.A (MDCLF) current stock price?

As of the latest data, MedinCell S.A stock price is $34.39, with a previous close of $34.39.

What is MedinCell S.A (MDCLF) current market capitalization?

MedinCell S.A market cap is approximately 1.24 billion.

What is MedinCell S.A (MDCLF) Earnings Per Share (EPS)?

The trailing EPS is -$1.09.

Does MedinCell S.A (MDCLF) pay dividends?

No. MedinCell S.A does not pay a dividend.

When is MedinCell S.A (MDCLF) next earnings report?

MedinCell S.A is expected to release its next earnings report on September 30, 2026.

What is MedinCell S.A (MDCLF) beta (volatility) score?

MedinCell S.A has a beta of 0.917, meaning its volatility is roughly in line with the market.